Loading...
•
Dec 31, 2020
Ultragenyx Q4 2020 Earnings Report
Ultragenyx reported Q4 2020 financial results and provided a corporate update.
Key Takeaways
Ultragenyx reported total revenue of $91.5 million for the fourth quarter of 2020. The company had a net loss of $24.0 million, or $0.37 per share. They reaffirmed the 2021 guidance range for Crysvita of $180 million to $190 million.
Total revenue for the fourth quarter of 2020 was $91.5 million.
Crysvita revenue in Ultragenyx territories was $40.4 million for Q4 2020.
Dojolvi product sales were $6.4 million in the fourth quarter of 2020.
Net loss for the fourth quarter of 2020 was $24.0 million, or $0.37 per share.
Revenue by Segment
Forward Guidance
The company reaffirms the 2021 guidance range for Crysvita that was provided at the beginning of the year. This range is $180 million to $190 million for the North American profit share region and the other regions where product sales are recognized (Latin America and Turkey).
Positive Outlook
- Initiate a Phase 3 study for DTX401 for Glycogen Storage Disease Type Ia (GSDIa) in the first half of 2021.
- Initiate a Phase 3 study for DTX301 for Ornithine Transcarbamylase (OTC) Deficiency in the second half of 2021.
- Initiate a Phase 1/2/3 study for UX701 for Wilson disease in the first half of 2021.
- Resume enrollment and dosing in the Phase 1/2 study for GTX-102 for Angelman Syndrome in the first half of 2021.
- Conduct a Phase 2/3 study in pediatric patients for UX143 (setrusumab) for Osteogenesis Imperfecta, anticipated in second half of 2021.
Challenges Ahead
- Uncertainty and potential delays related to clinical drug development.
- Smaller than anticipated market opportunities for the company’s products and product candidates.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...